Laekna, Inc. announced that the Centre for Drug Evaluation of the National Medical Products Administration of China has accepted the Investigational New Drug (IND) application for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of adult patients with obesity or metabolic diseases. The Company is pleased of the IND application acceptance of LAE102 and will work closely with the regulatory authorities to complete the application. The Company would commence the clinical trial process after obtaining the IND approval and is committed to bring this precision therapy to obesity or metabolic patients who are in need of novel treatment options.